|
February 2003 (v03-n02) |
|
- Main Story - pgs. 1-8 Ęterna Laboratories
- Macro Market Commentary - pgs. 9-10
- Recommended Readings - pg. 11
- Biotech Monthly Coverage Update - pg. 12-18
- NIBM Model
Portfolio - pg. 19
- (Full outline below...)
|
 |
|
| This month's Main Story explores small-cap
conglomerate Ęterna Laboratories. What drew the NIBM Research Team to this company is its
"good dirty" anti-angiogenesis cancer treatment Neovastat. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Ęterna Laboratories
- Introduction
- Table: Basic Facts
- Disclosures
- Investment Case
- Table: Recent Organizational Events
- Chart: Organizational Structure
- Atrium Biotechnologies
- Unipex
- Zentaris AG
- Table: Zentaris AG Products
- Neovastat
- Angiogenesis
- Table: VEGF Inhibitors in clinical trials
- Neovastat clinical indications
- Renal cancer
- Non-small cell lung cancer (NSCLC)
- Multiple myeloma
- Prostate cancer
- Psoriasis
- Age-related macular degeneration (AMD)
- Why we like Neovastat
- Methods of action
Table: Ęterna Milestones
What Can Go Wrong
Macro Market Commentary
Recommended Readings
- Biotech Monthly Coverage Updates
- Dendreon
- General reaction to Corvas acquisition
- Finances
- Science
- Deal mechanics
- Commentary
- Genta
- ID Biomedical
- AVANT Immunotherapeutics
- Onyx Pharmaceuticals
- Targeted Genetics
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
